文献速递产科母胎医学

阿司匹林用于基于证据的子痫前期预防试验:阿司匹林在不同特征及内科和产科病史亚组女性中预防早产子痫前期的效果

Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history.
PubMed 文献 · Am J Obstet Gynecol · 2017-08-04

该研究为阿司匹林用于基于证据的子痫前期预防试验的二次分析,评估阿司匹林对早产子痫前期发生率的影响在不同母体特征及病史亚组中是否存在差异。结果显示,在慢性高血压孕妇中阿司匹林组早产子痫前期发生率为10.2%(5/49),安慰剂组为8.2%(5/61),校正比值比为1.29(95%置信区间0.33-5.12);无慢性高血压者中分别为1.1%(8/749)和3.9%(30/761),校正比值比为0.27(95%置信区间0.12-0.60)。结论认为阿司匹林预防早产子痫前期的获益可能不适用于合并慢性高血压的妊娠。

要点

  • 在慢性高血压孕妇中,阿司匹林组早产子痫前期发生率为10.2%(5/49),安慰剂组为8.2%(5/61),校正比值比为1.29(95%置信区间0.33-5.12)。
  • 在无慢性高血压孕妇中,阿司匹林组早产子痫前期发生率为1.1%(8/749),安慰剂组为3.9%(30/761),校正比值比为0.27(95%置信区间0.12-0.60)。
  • 在服药依从性≥90%的参与者中,慢性高血压亚组的校正比值比为2.06(95%置信区间0.40-10.71),无慢性高血压亚组的校正比值比为0.05(95%置信区间0.01-0.41)。

核心结论

  • 阿司匹林预防早产子痫前期的有益效果可能不适用于合并慢性高血压的妊娠。
  • 在根据母体特征和产科病史定义的亚组中,未发现阿司匹林效果存在异质性的证据。

研究设计与样本

  • 本研究为阿司匹林用于基于证据的子痫前期预防试验的二次分析。
  • 亚组分析按产妇年龄(<30岁和≥30岁)、体重指数(<25和≥25 kg/m2)、种族来源(非裔加勒比、白种人和其他)、受孕方式(自然和辅助)、吸烟(吸烟者和不吸烟者)、早产子痫前期家族史(有和无)、产科病史(未产、经产有既往早产子痫前期和经产无既往早产子痫前期)、慢性高血压病史(有和无)定义亚组。
  • 交互作用检验在全数据集的意向治疗人群和服药量≥90%处方药物的患者数据集上进行。

主要发现

  • 在慢性高血压参与者中,阿司匹林组早产子痫前期发生率为10.2%(5/49),安慰剂组为8.2%(5/61),校正比值比为1.29(95%置信区间0.33-5.12)。
  • 在无慢性高血压参与者中,阿司匹林组早产子痫前期发生率为1.1%(8/749),安慰剂组为3.9%(30/761),校正比值比为0.27(95%置信区间0.12-0.60)。
  • 在服药依从性≥90%的参与者中,阿司匹林组的校正比值比为0.24(95%置信区间0.09-0.65);在慢性高血压亚组中为2.06(95%置信区间0.40-10.71);在无慢性高血压亚组中为0.05(95%置信区间0.01-0.41)。
  • 对于完整数据集,交互作用检验在5%水平上未达统计学显著(P=0.055),但在服药依从性≥90%者中,经多重比较校正后,交互作用在5%水平上显著(P=0.0019)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for Evidence-Based Preeclampsia Prevention trial demonstrated that in women who were at high risk for preterm preeclampsia with delivery at <37 weeks' gestation identified by screening by means of an algorithm that combines maternal factors and biomarkers at 11-13 weeks' gestation, aspirin administration from 11 to 14 until 36 weeks' gestation was associated with a significant reduction in the incidence of preterm preeclampsia (odds ratio 0.38; 95% confidence interval, 0.20 to 0.74; P=0.004). OBJECTIVE: We sought to examine whether there are differences in the effect of aspirin on the incidence of preterm preeclampsia in the Aspirin for Evidence-Based Preeclampsia Prevention trial in subgroups defined according to maternal characteristics and medical and obstetrical history. STUDY DESIGN: This was a secondary analysis of data from the Aspirin for Evidence-Based Preeclampsia Prevention trial. Subgroup analysis was performed to assess evidence of differences in the effect of aspirin on incidence of preterm preeclampsia in subgroups defined by maternal age (<30 and ≥30 years), body mass index (<25 and ≥25 kg/m2), racial origin (Afro-Caribbean, Caucasian and other), method of conception (natural and assisted), cigarette smoking (smoker and non-smoker), family history of preterm preeclampsia (present and absent), obstetrical history (nulliparous, multiparous with previous preterm preeclampsia and multiparous without previous preterm preeclampsia), history of chronic hypertension (present and absent). Interaction tests were performed on the full data set of patients in the intention to treat population and on the data set of patients who took ≥ 90% of the prescribed medication. Results are presented as forest plot with P values for the interaction effects, group sizes, event counts and estimated odds ratios. We examined whether the test of interaction was significant at the 5% level with a Bonferroni adjustment for multiple comparisons. RESULTS: There was no evidence of heterogeneity in the aspirin effect in subgroups defined according to maternal characteristics and obstetrical history. In participants with chronic hypertension preterm preeclampsia occurred in 10.2% (5/49) in the aspirin group and 8.2% (5/61) in the placebo group (adjusted odds ratio, 1.29; 95% confidence interval, 0.33-5.12). The respective values in those without chronic hypertension were 1.1% (8/749) in the aspirin group and 3.9% (30/761) in the placebo group (adjusted odds ratio, 0.27; 95% confidence interval, 0.12-0.60). In all participants with adherence of ≥90% the adjusted odds ratio in the aspirin group was 0.24 (95% confidence interval, 0.09-0.65); in the subgroup with chronic hypertension it was 2.06 (95% confidence interval, 0.40-10.71); and in those without chronic hypertension it was 0.05 (95% confidence interval, 0.01-0.41). For the complete data set the test of interaction was not significant at the 5% level (P = .055), but in those with adherence ≥90%, after adjustment for multiple comparisons, the interaction was significant at the 5% level (P = .0019). CONCLUSION: The beneficial effect of aspirin in the prevention of preterm preeclampsia may not apply in pregnancies with chronic hypertension. There was no evidence of heterogeneity in the aspirin effect in subgroups defined according to maternal characteristics and obstetrical history.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Poon LC, Wright D, Rolnik DL, et al. Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. Am J Obstet Gynecol. 2017. PMID: 28784417. doi:10.1016/j.ajog.2017.07.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。